Video

Risk Stratification of Patients with Prostate Cancer

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC, FACS

Michael Cookson, MD, MMHC, explains the NCCN criteria used to stratify patients with clinically localized prostate cancer into risk groups.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial
      Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial
      Timothy McClure, MD, on next steps for focal therapy in prostate cancer
      Timothy McClure, MD, on next steps for focal therapy in prostate cancer
      Kevin Shee, MD, outlines factors linked with recurrence after HIFU
      Kevin Shee, MD, outlines factors linked with recurrence after HIFU
      Related Content
      Survey data shows lack of awareness on prostate, testicular cancer
      August 29th 2025

      Survey data shows lack of awareness on prostate, testicular cancer

      Hannah Clarke
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      August 29th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Downloaded Save to Library Preview Crop Find Similar File #: 322782977 Abstract tech background made of printed circuit board. Depth of field effect and bokeh. internet connections, cloud computing and neural network, big data. 3D render | Image Credit: © Quardia Inc. - stock.adobe.com
      August 29th 2025

      AI and prostate cancer: Balancing hope and caution

      Christopher Weight, MD, MS
      Dr. Murphy on increasing diversity in cancer clinical trials
      August 29th 2025

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      Health Canada approves darolutamide for metastatic castration-sensitive prostate cancer
      August 29th 2025

      Health Canada approves darolutamide for metastatic castration-sensitive prostate cancer

      Hannah Clarke
      Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health
      August 29th 2025

      Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health

      Hannah Clarke
      © 2025 MJH Life Sciences

      All rights reserved.